Bio

Mitchell Stern has over 30 years of investment banking experience, having closed over 40 transactions totaling more than $4 billion in aggregate value. Mr. Stern joined Dresner Partners in January 2012 as a Managing Director responsible for the Healthcare sector. Before joining Dresner Partners, Mr. Stern was a Managing Director in Healthcare Investment Banking at Morgan Joseph. He has also held positions with SMH Capital (Sanders Morris Harris), Glocap Advisors, Needham & Co., Schroders plc (Wertheim Schroder), and Salomon Brothers. In addition, Mr. Stern worked for the M&A Transactions Group at Deloitte & Touche and was a Certified Public Accountant (C.P.A.) with Ernst and Whinney (now Ernst & Young). Mr. Stern has been involved in a variety of domestic and cross-border middle market valuation, capital raising and M&A transactions in the areas of healthcare services/healthcare IT, medical devices/products, and nutraceuticals/pharmaceuticals. Within healthcare services/HCIT, Mr. Stern has worked on some of the largest transactions in the long-term care sector, including the $1.4 billion acquisition of The Multicare Companies by Genesis Health Ventures, Texas Pacific Group and Cypress Group. He has also worked on the initial public offering for United Payors & United Providers (specialty managed care); the sale of Millennix (CRO) to IT&E International and The Comvest Group; and a follow-on offering for HBO & Co. (healthcare information systems) prior to its sale to McKesson. In medical products/life sciences, Mr. Stern has worked on financings for Innotech (ophthalmology devices) prior to its sale to J&J; ValveXchange (heart valves), Neurex (pain management) and Medgenics (protein therapeutics), as well as the merger of four publicly-traded companies into ICN Pharmaceuticals and the sale of Alan James Group (nutraceuticals) to Interleukin Genetics. Mr. Stern is the leading investment banker in the fertility (IVF) sector, having closed numerous transactions including the sale of IGENOMIX, the merger of RMANJ and IVI of Spain, the sale of Advanced Fertility of Chicago to Prelude Fertility (now Inception), the sale of Santa Monica Fertility to Webster Equity Partners, the sale of InVia Fertility to In Vitro Sciences (now First Fertility), the sale of Institute for Human Reproduction to Pinnacle Fertility, the sale of Dominion Fertility to Pinnacle Fertility, the sale of Center of Reproductive Medicine to US Fertility, the sale of IVF1 to Pinnacle Fertility, the sale of Fertility Institute of New Jersey & New York to Axia Women's Health, and the sale of RADfertility to CCRM. Mr. Stern specializes in M&A for clinic-based businesses, including physician practices. Mr. Stern recently completed the sale of New Horizons Center for Cosmetic Surgery in Chicago and is working with numerous parties in the cosmetic / reconstructive surgery and medical spa space.